Dr Reddy's Labs

how big is Dr Reddy's Labs?

As of Jun 06, Dr Reddy's Laboratories Ltd has a market capitalization of 110,231.55 Cr, with recent net sales of 32,643.90 Cr and net profit of 5,655.10 Cr over the last four quarters. Shareholder's funds are 28,254.80 Cr, and total assets amount to 37,806.00 Cr as of Mar'24.

Market Cap: As of Jun 06, Dr Reddy's Laboratories Ltd has a market capitalization of 110,231.55 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 32,643.90 Cr, and the sum of Net Profit is 5,655.10 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the reporting period of Mar'24. The Shareholder's Funds amount to 28,254.80 Cr, and the Total Assets are 37,806.00 Cr.

When is the next results date for Dr Reddy's Labs?

No Upcoming Board Meetings

What is the bonus history of the Dr Reddy's Labs?

Dr. Reddy's Laboratories issued a 1:1 bonus on August 28, 2006, allowing shareholders to double their holdings by receiving an additional share for each share owned, with the record date set for August 29, 2006.

Dr. Reddy's Laboratories has a bonus history that includes a notable 1:1 bonus issue announced on August 28, 2006. The record date for this bonus was August 29, 2006. This means that for every share held, shareholders received an additional share, effectively doubling their holdings at that time. If you have any more questions about the company or its financials, feel free to ask!

Has Dr Reddy's Labs declared dividend?

Yes, Dr Reddy's Laboratories has declared an 800% dividend, amounting to ₹40 per share, with an ex-date of July 16, 2024. The company has demonstrated strong total returns across various periods, with a total return of 15.2% over the past year.

Dr Reddy's Laboratories Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 40<BR>- Ex-date: 16 Jul 24<BR><BR>Dividend Yield: 0.62%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.26%, with no dividend return, resulting in a total return of 5.26%.<BR><BR>Over the past year, the price return was 11.89%, the dividend return was 3.31%, leading to a total return of 15.2%.<BR><BR>In the 2-year period, the price return was 42.35%, the dividend return was 8.21%, culminating in a total return of 50.56%.<BR><BR>For the last 3 years, the price return was 53.12%, with a dividend return of 12.94%, resulting in a total return of 66.06%.<BR><BR>In the 4-year timeframe, the price return was 25.6%, the dividend return was 12.49%, giving a total return of 38.09%.<BR><BR>Lastly, over the past 5 years, the price return was 63.89%, with a dividend return of 20.41%, leading to a total return of 84.3%.<BR><BR>Overall, Dr Reddy's Laboratories has declared a substantial dividend while also showing strong total returns across multiple periods, indicating a positive financial performance for the company.

Who are the peers of the Dr Reddy's Labs?

Dr Reddy's Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci, Lupin, Abbott India, and Aurobindo Pharma. In terms of performance, Divi's Lab leads with a 1-year return of 49.58%, while Dr Reddy's Labs has a return of -5.19%.

Peers: The peers of Dr Reddy's Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci., Lupin, Abbott India, and Aurobindo Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Aurobindo Pharma, while Average management risk is found at Lupin and Glenmark Pharma. Growth is excellent for Sun Pharma.Inds., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is noted for Divi's Lab., Torrent Pharma, and Aurobindo Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, Mankind Pharma, Dr Reddy's Labs, Zydus Lifesci., Abbott India, and Aurobindo Pharma, while good capital structure is found at Torrent Pharma and Lupin, and Glenmark Pharma has average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 49.58%, while Zydus Lifesci. has the lowest at -18.37%, with Dr Reddy's Labs showing a 1-year return of -5.19%, which is higher than Zydus Lifesci. but lower than Divi's Lab. Additionally, Zydus Lifesci., Lupin, and Aurobindo Pharma have negative six-month returns.

Who are in the management team of Dr Reddy's Labs?

As of March 2022, the management team of Dr Reddy's Labs includes G V Prasad (Co-Chairman & Managing Director), K Satish Reddy (Executive Chairman), and several independent directors, including Kalpana Morparia and Leo Puri, among others. This team is responsible for the company's strategic direction and governance.

As of March 2022, the management team of Dr Reddy's Labs includes the following individuals:<BR><BR>1. G V Prasad - Co-Chairman & Managing Director<BR>2. K Satish Reddy - Executive Chairman<BR>3. Kalpana Morparia - Independent Director<BR>4. Shikha Sanjaya Sharma - Independent Director<BR>5. Leo Puri - Independent Director<BR>6. K P Krishnan - Independent Director<BR>7. Pennv Wan - Independent Director<BR>8. K Randhir Singh - Company Secretary & Compliance Officer<BR>9. Arun M. Kumar - Independent Director<BR>10. Claudio Albrecht - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

What does Dr Reddy's Labs do?

Dr Reddy's Laboratories Limited is a global pharmaceutical company that offers affordable and innovative medicines, with a market cap of INR 104,919 Cr and a net profit of INR 15,933 Cr as of March 2025. Key metrics include a P/E ratio of 19.00 and a dividend yield of 1.27%.

Overview:<BR>Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company that provides affordable and innovative medicines, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Dr Reddy's Laboratories was incorporated in the year N/A. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 85,284 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 15,933 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: INR 104,919 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 1.27%<BR>- Debt Equity: -0.03<BR>- Return on Equity: 16.86%<BR>- Price to Book: 3.13<BR><BR>Contact Details:<BR>Address: 8-2-337 Road No 3, Banjara Hills Hyderabad Telangana : 500034<BR>Tel: 91-40-49002900<BR>Email: shares@drreddys.com<BR>Website: http://www.drreddys.com

Who are the top shareholders of the Dr Reddy's Labs?

The top shareholders of Dr Reddy's Labs include promoter G V Prasad with 11.52%, J P Morgan Chase Bank Na as the largest public shareholder at 11.54%, mutual funds holding 12.89%, foreign institutional investors at 25.75%, and individual investors with approximately 8.2%.

The top shareholders of Dr Reddy's Labs include several key players. The majority shareholders are the promoters, with G V Prasad being the promoter with the highest holding at 11.52%. In the public domain, J P Morgan Chase Bank Na holds a significant stake of 11.54%, making it the highest public shareholder. Additionally, mutual funds collectively hold 12.89% through 38 schemes, while foreign institutional investors (FIIs) account for 25.75% with 799 FIIs involved. Individual investors hold around 8.2% of the shares.

Are Dr Reddy's Labs latest results good or bad?

Dr. Reddy's Laboratories reported a net profit of ₹1,340.80 crores for Q2 FY26, a 7.30% year-on-year increase, and net sales grew by 9.83%. However, profitability concerns arise from a 5.44% quarter-on-quarter decline in net profit and reduced operating margins, indicating challenges in cost management.

Dr. Reddy's Laboratories' latest results present a mixed picture. On one hand, the company achieved a net profit of ₹1,340.80 crores for Q2 FY26, which is a 7.30% increase year-on-year. Additionally, net sales reached ₹8,828.30 crores, reflecting a 9.83% growth compared to the same quarter last year and a 2.99% increase from the previous quarter.<BR><BR>However, there are notable concerns regarding profitability. The net profit decreased by 5.44% quarter-on-quarter, and the operating margin fell to 22.77% from 25.36% in the previous quarter, indicating increased cost pressures. The profit after tax (PAT) margin also declined to 15.07% from 16.45%, highlighting challenges in maintaining profitability amidst rising operational costs.<BR><BR>Overall, while revenue growth is a positive aspect, the decline in margins and net profit suggests that the company is facing significant headwinds in terms of cost management and pricing pressures in the pharmaceutical sector. Investors may want to keep an eye on how the company addresses these margin compression issues in the coming quarters.

Is Dr Reddy's Labs overvalued or undervalued?

As of October 27, 2025, Dr Reddy's Labs is fairly valued with a PE ratio of 18.57, lower than its peers like Sun Pharma and Divi's Lab, despite recent underperformance compared to the Sensex.

As of 27 October 2025, Dr Reddy's Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 18.57, an EV to EBITDA ratio of 11.31, and a Price to Book Value of 0.30, which indicate a reasonable valuation compared to its peers.<BR><BR>In comparison to its peers, Dr Reddy's Labs has a lower PE ratio than Sun Pharma (35.43) and Divi's Lab (74.62), both of which are classified as expensive. Additionally, it is on par with Cipla (PE of 23.74) and Zydus Lifesciences (PE of 21.52), which are also attractive. Despite a recent underperformance relative to the Sensex over the past year, where Dr Reddy's returned -1.40% compared to the Sensex's 6.77%, the valuation metrics suggest that the stock is currently fairly valued in the market.

Is Dr Reddy's Labs technically bullish or bearish?

As of November 28, 2025, Dr Reddy's Labs shows a mildly bullish trend based on daily moving averages and weekly Dow Theory, despite mixed signals from weekly MACD and KST indicators.

As of 28 November 2025, the technical trend for Dr Reddy's Labs has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD and KST are bearish, suggesting mixed signals. The weekly Dow Theory shows a mildly bullish trend, but the monthly indicators remain mostly bearish or neutral. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly Dow Theory, despite the bearish signals from MACD and KST on the weekly time frame.

How has been the historical performance of Dr Reddy's Labs?

Dr Reddy's Labs has shown consistent growth from Mar'20 to Mar'25, with net sales increasing from 17,517 Cr to 32,643.90 Cr and profit after tax rising from 1,969.90 Cr to 5,703.50 Cr. The company has maintained positive cash flow and expanded its total assets significantly, reflecting strong financial health.

Answer:<BR>The historical performance of Dr Reddy's Labs shows a consistent growth trajectory in net sales, with figures rising from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Total operating income has mirrored this trend, increasing from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25. Operating profit (PBDIT) has also seen significant growth, climbing from 3,091.00 Cr in Mar'20 to 9,644.40 Cr in Mar'25, although the operating profit margin has fluctuated, peaking at 28.42% in Mar'24 before dropping to 26.26% in Mar'25. Profit before tax has increased from 1,829.60 Cr in Mar'20 to 7,657.80 Cr in Mar'25, while profit after tax has risen from 1,969.90 Cr to 5,703.50 Cr over the same period. The company's total assets have grown from 22,005.40 Cr in Mar'20 to 47,594.10 Cr in Mar'25, reflecting a strong balance sheet, while total liabilities have also increased, from 22,005.40 Cr to 47,594.10 Cr. Cash flow from operating activities has shown a positive trend, increasing from 2,984.00 Cr in Mar'20 to 4,642.00 Cr in Mar'25, contributing to a net cash inflow of 748.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Reddy's Labs has demonstrated robust growth in net sales, which rose from 17,517.00 Cr in Mar'20 to 32,643.90 Cr in Mar'25, indicating a strong demand for its products. The total operating income followed suit, reflecting the same upward trend. Operating profit (PBDIT) has significantly increased, reaching 9,644.40 Cr in Mar'25, although the operating profit margin experienced some volatility. Profit before tax surged to 7,657.80 Cr, while profit after tax reached 5,703.50 Cr, showcasing the company's improving profitability. The total assets of Dr Reddy's Labs expanded considerably, reflecting its growth strategy, while total liabilities also increased, indicating a corresponding rise in financial obligations. The cash flow from operating activities has remained positive, contributing to a net cash inflow, which further underscores the company's solid financial health and operational efficiency.

Why is Dr Reddys Laboratories Ltd falling/rising?

As of 16-Mar, Dr Reddys Laboratories Ltd's stock price is 1,275.05, down 1.39% and has declined for three consecutive days, totaling a 3.81% drop. Despite strong long-term fundamentals, current market sentiment is negatively impacting the stock's performance.

As of 16-Mar, Dr Reddys Laboratories Ltd is experiencing a decline in its stock price, currently at 1,275.05, which reflects a change of -17.95 (-1.39%). The stock has been underperforming, having lost value for three consecutive days, resulting in a total decline of -3.81% during this period. Additionally, the stock's performance today has underperformed the sector by -0.27%. <BR><BR>The stock touched an intraday low of Rs 1263.35, indicating a drop of -2.29%. Furthermore, there has been a decrease in investor participation, with delivery volume falling by -11.2% against the five-day average. Although the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, suggesting a short-term weakness.<BR><BR>Despite these negative indicators, the company has strong long-term fundamentals, including low debt and healthy growth in net sales and operating profit. However, the current market sentiment appears to be affecting the stock negatively, leading to its recent price decline.

Which are the latest news on Dr Reddy's Labs?

Should I buy, sell or hold Dr Reddys Laboratories Ltd?